In Brief This Week: Danaher; Sequenom; Complete Genomics; PerkinElmer; GnuBio; Novozymes, Morphosys; OGI | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Danaher's board of directors approved a quarterly dividend of $.025 per share payable on Jan. 27, 2012 to holders of record on Dec. 30, 2011.


Sequenom said this week that it has been upgraded from the Nasdaq Global Market to the Nasdaq Global Select Market. It will continue to trade under the ticker symbol "SQNM" and will transfer its listing starting Jan. 3, 2012.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.